Jonathan Schatz

Has grant

Associate Professor

University of Miami School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

A New Treatment Paradigm for ALK-Driven Cancers Exploiting Oncogene Overdose

Open Date: 2014-09-19

Close Date: 2019-08-31

Articles (21)

Year:

2026

Chimeric antigen receptor T-cell (CAR T) therapy has advanced treatment for B-cell lymphoma (BCL), but >50% of patients relapse. Predicting clinical outcomes based on features at CAR T infusion remains unclear, and most trials lack racial diversity, limiting understanding of its impact on outcomes. To address these challenges, we pooled data from 9 CAR T clinical trials, consisting of 2304 patients with BCL. The nature of this data set, made available through the Medidata Clinical Cloud, represents a large set of patient-level data aggregated over 9 clinical trials that has not been previously analyzed in this manner. Of the 2304 patients, 395 (17.1%) failed screening, and 1637 were assigned CAR T; 151 (9.22%) did not receive treatment due to adverse events, disease progression, or death, with only 12% surviving at 1 year. For treated patients, we analyzed 2 cohorts: large BCL (LBCL, n = 958) and indolent BCL (iBCL, n = 349). Multivariate Cox models revealed that low performance status and high tumor burden (Eastern Cooperative Oncology Group ≥2, bulky disease, bridging therapy) negatively affected overall survival (OS) and progression-free survival (PFS) in LBCL, whereas age and shorter time from diagnosis to infusion negatively impacted OS and PFS in iBCL. Despite the underrepresentation of non-White groups across all trial phases, the feasibility and effectiveness of CAR T therapy were consistent across racial and ethnic groups.

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline combination chemoimmunotherapy, DLBCL carries persistently poor prognosis for those with relapsed or refractory (rel/ref) disease, despite recent advances in immunotherapy. Here, we build on recent findings implicating gain-of-function mutations in the BCL10 signaling protein as drivers of resistance to Bruton’s tyrosine kinase (BTK) inhibitors. We show mutant BCL10-driven DLBCL is resistant to multiple additional drug classes, demonstrating urgency to derive mechanistically rooted strategies to overcome undruggable BCL10 mutants that stabilize BTK-independent signaling filaments upstream of NF-kB activation. BCL10 mutants promote a cytokine-reinforced positive feedback loop of lymphomagenesis driving not just NF-kB but multiple additional pathways converging on diffuse activation of oncogenic transcription factors. Up-regulation of anti-apoptotic genes increases mitochondrial membrane potential, underlying multidrug resistance. Increased expression of BCL2 , BCL2L1 ( BCL-XL ), and BCL2A1 ( BFL1 ) drives resistance to venetoclax, but expression can be overcome by the potent non-covalent BTK inhibitor pirtobrutinib. Venetoclax plus pirtobrutinib synergized in overcoming resistance and potently killed BCL10-mutant lymphomas in vitro and in vivo. BTK therefore retains key roles protecting DLBCL from apoptosis even when downstream activation of the BCL10 signaling complex activates NF-kB independently.

Year:

2025

Figure S1: Overview of the Single-Cell Expansion Model. Figure S2: Mutational Profiles of Chemoradiotherapy-Treated Lymphoid Patients. Figure S3: ID83 signature relationships to SBS96 signatures in newly diagnosed MM and BCL. Figure S4: ID8-associated Peaks in ID8-negative Cases. Figure S5: Indel profiles of select ID8-positive subgroups. Figure S6: Similarity of ID8 Regardless of Disease Histology. Figure S7: Genomic Complexity has No Bearing on ID8 Contribution. Figure S8: De novo SBS96 and ID83 extractions for single-cell derived colonies. Figure S9: De-noised SBS96 profiles. Figure S10: De-noised ID83 Profiles. Figure S11: ID8 Fitting to a Melphalan-exposed Cell Line. Figure S12: Median profiles of sublethal-dose platinum and RT single-cell-derived colonies showing global contribution of ID8 in both exposure types. Figure S13: ID8 presence in t-MN.

Year:

2025

Table S1: Demographic Data. Table S2: Exposure History LBCL. Table S3: Exposure History Myeloma. Tables S4: Exposure History for t-MN from PMID: 36626250. Table S5: ID83 Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S6: Mutational Signatures Contribution for the Patient-Level Lymphoid Cohort. Table S8: ID8 is independent of genomic complexity in MM. p-values reflect wilcoxcon test of ID8 positive cases stratified by genomic. Table S9: Characteristics of single-cell-derived colonies. Table S10: Viability of DHL-4 cells post treatment (in 10^3 cells). Table S11: De novo mutional signatures extraction for single-cell-derived colonies. Table S12: De novo signature contributions for each colony. Table S13: Signal to Noise Ratios for ChemoRT-Exposed Single Cell-Derived Colonies. Table S14: De-noised mutational and indel signatures fitting of single-cell-derived colonies. Table S15: ID signature fitting to indel profiles of an induced pluripotent stem cell line (Kucab and colleagues, 2019) exposed to various mutagenic and non-mutagenic chemotherapies. Table S16: Indel Signature Re-fit for t-MN samples

Year:

2025

Cancers co-opt stress response pathways to drive oncogenesis, dodge immune surveillance, and resist cytotoxic therapies. Several of these pathways also provide protection from ferroptosis, an iron-dependent oxidative cell death pathway triggered by clinically available drugs, including chemotherapies, rheumatologic agents, and novel ferroptosis inducers under evaluation in clinical trials. In this study, we found that disrupting cap-dependent translation initiation in diffuse large B-cell lymphoma (DLBCL) sensitizes cells to ferroptosis. Specifically, the eIF4A1 inhibitor zotatifin synergized with pharmacologic ferroptosis inducers primarily through suppression of glutathione production, which protects polyunsaturated fatty acids from ferroptotic oxidation. Loss of nuclear factor erythroid 2–related factor 2 (NRF2) translation, a master regulator of antioxidant genes, was a key consequence of rocaglates, including zotatifin, and other disruptors of cap-dependent initiation. Although NRF2 loss alone was insufficient to trigger ferroptosis, it lowered the antioxidant threshold, sensitizing cells to lipid peroxidation and ferroptotic death under additional oxidative stress. In vivo , combining zotatifin with the optimized ferroptosis inducer imidazole ketone erastin significantly reduced tumor burden in DLBCL patient-derived xenografts. Treatment with zotatifin in combination with chimeric antigen receptor (CAR) T cells, a vital treatment modality for patients with DLBCL, revealed that zotatifin preexposure sensitized DLBCL tumors to CD19-directed CAR T cells in vitro and extended survival of CAR T-cell–treated immunocompetent mice bearing syngeneic DLBCL tumors in vivo . Overall, eIF4A1 inhibition–induced translational disruption provides opportunities to leverage the therapeutic impacts of ferroptosis inducers, including cytotoxic immunotherapies. Significance: Translational disruption causes NRF2 loss that sensitizes lymphomas to ferroptosis and enhances CAR T-cell and drug efficacy, highlighting eIF4A1 targeting as a promising therapeutic strategy for treating cancer.

Year:

2025

Ionizing radiotherapy (RT) is a widely used treatment strategy for malignancies. In solid tumors, RT-induced double-strand breaks lead to the accumulation of insertion-deletions (indels; ID), and their repair by nonhomologous end joining has been linked to the ID8 mutational signature in surviving cells. However, the extent of RT-induced mutagenesis in hematologic malignancies and its impact on their mutational profiles and interplay with commonly used chemotherapies has not yet been explored. In this study, we interrogated 580 whole-genome sequence (WGS) samples from patients with large B-cell lymphoma, multiple myeloma, and myeloid neoplasms and identified ID8 only in relapsed disease. Yet ID8 was detected after exposure to both RT and mutagenic chemotherapy (i.e., platinum and melphalan). Using WGS of single-cell colonies derived from treated lymphoma cells, we revealed a dose–response relationship between RT and platinum and ID8. Finally, using ID8 as a genomic barcode, we demonstrate that a single RT-surviving cell may seed distant relapse. Significance: RT and the ID8 indel signature are related, but their genomic impact on hematologic malignancies is unclear. Leveraging WGS, we linked ID8 to both RT and mutagenic chemotherapy and validated that platinum can induce ID8. We used ID8 as a genomic barcode to reveal that RT-resistant cells may seed systemic relapse.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (18)

Dionysios Watson

University of Miami School of Medicine

UNITED STATES
View details

Ola Landgren

Professor of Medicine

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details

Claude-Henry Volmar

Associate Professor

University of Miami Miller School of Medicine

UNITED STATES
View details

Roland Fenk

Prof. Dr

University Hospital Düsseldorf

GERMANY
View details

Bachisio Ziccheddu

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details

Hassan A Ali

University of Miami

UNITED STATES
View details

Michele Ceccarelli

Research Professor at University of Miami

University of Miami

UNITED STATES
View details

Katja C. Weisel

University Medical Center Hamburg-Eppendorf

GERMANY
View details

Gon Sup Kim

Sylvester Comprehensive Cancer Center

UNITED STATES
View details

Saad Usmani

Chief Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Emmanuel Stylianos Antonarakis

Professor of Medicine, Associate Director for Translation

-

UNITED STATES
View details

Tomas Jelinek

-

CZECH REPUBLIC
View details

Michael Jain

Associate Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Edus Warren

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Marco Vincenzo Russo

Senior Research Scientist

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Francesco Maura

Assistant Professor

Sylvester Comprehensive Cancer Center

UNITED STATES
View details

Marc S. Raab

University Hospital Heidelberg

GERMANY
View details

Ping Luo

Assistant Professor

Algoma University

CANADA
View details